Drägerwerk stock weighs stronger sales against Q3 margin pressure

Published on 11/10/2026 at 10:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock enters the final quarter with stronger orders but a weaker third-quarter margin. Management kept its 2026 targets.

Sales Growth Meets Margin Pressure

Currency-adjusted nine-month sales rose 5.3 percent, led by growth in both Medical and Safety Technology.
Third-quarter EBIT fell year on year as higher functional expenses outweighed stronger order intake.
Drägerwerk kept its 2026 targets for currency-adjusted sales growth and EBIT margin unchanged.

Drägerwerk, DE0005550636, Illustration mit AI erstellt.

Drägerwerk reported stronger business in the first nine months of 2026, but the third quarter showed renewed pressure on profitability. In the release carried by Deutsche Börse, dated October 29, the company said order intake increased to 2,673.5 million euros in the nine-month period from 2,594.1 million euros a year earlier.

Currency-adjusted net sales rose 5.3 percent to 2,453.9 million euros. Medical Technology sales increased 4.4 percent to 1,367.0 million euros, while Safety Technology sales advanced 6.5 percent to 1,087.0 million euros. The split matters for investors because the safety business delivered the stronger growth rate and also reported higher order intake.

Orders Improve, Quarterly Profit Slips

Group order intake increased 7.0 percent on a currency-adjusted basis to 926.2 million euros in the third quarter. Safety Technology led the development with a 20.2 percent rise to 451.9 million euros. Medical Technology order intake declined 3.0 percent to 474.3 million euros, with weaker demand in the EMEA region weighing on the division.

Quarterly net sales grew 1.0 percent on a currency-adjusted basis to 850.8 million euros. EBIT nevertheless fell to 48.0 million euros from 56.7 million euros in the prior-year quarter, while the EBIT margin narrowed to 5.6 percent from 6.8 percent. The company cited higher personnel, logistics and IT costs as the main drivers of the increase in functional expenses.

For the first nine months, EBIT rose to 111.8 million euros from 77.1 million euros and the margin improved to 4.6 percent from 3.3 percent. The comparison includes 27.9 million euros in customs refunds, with 20.1 million euros attributable to the third quarter. Dräger also said 25.8 million euros of U.S. customs expenses incurred in 2026 were nonrefundable under current law, making the quality and repeatability of the earnings improvement important considerations for investors.

Outlook Keeps Execution In Focus

Dräger maintained its 2026 forecast for currency-adjusted net sales growth of 2.0 to 6.0 percent and an EBIT margin of 6.0 to 8.0 percent. The stronger order intake supports the revenue outlook, but the weaker quarterly margin leaves cost control and the conversion of orders into profitable sales central to the final quarter.

The company describes Medical and Safety Technology as its two principal markets. Its investor-relations information says Dräger focuses on medical and safety products for hospitals, emergency services and industry, while its medium-term strategy emphasizes profitability, innovation and recurring business.

Drägerwerk stock traded at 101.70 euros on Lang & Schwarz at 10:00 CET on Tuesday, November 10, 2026, 0.10 percent below the Xetra close of Monday, November 9. The move keeps the market focus on whether stronger demand can offset the quarterly margin setback.